Cookies used for improved website experience

Siemens Healthineers and our partners use cookies and other similar technologies to operate the Siemens Healthineers websites and personalize content and ads. You may find out more about how we use cookies by clicking "Show details" or by referring to our Cookie Policy.
You may allow all cookies or select them individually. And you may change your consent and cookie preferences anytime by clicking on the "Review and change your consent" button on the Cookie Policy page.

Addressing the Rising Prevalence of Non-alcoholic Fatty Liver Disease

Dr. Zobair M. Younossi
Professor & Chairman of Medicine,
Inova Fairfax Hospital, Virginia
|2019-08-16

Globally, the prevalence of nonalcoholic steatohepatitis (NASH) is rapidly growing. In the U.S. it is now the second leading indicator for liver transplantation and one of the top three causes of liver cancer. In this video, Dr. Zobair M. Younossi, Professor and Chairman of the Department of Medicine at Inova Fairfax Hospital in Falls Church, Virginia, discusses the epidemiology of nonalcoholic fatty liver disease (NAFLD), addressing why there is a global need for more awareness and why the current approach to clinical care needs to change.